Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 50 for “"lenalidomide"”.
-
Overcoming lenalidomide resistance in del(5q) myelodysplastic syndrome
… abnormality in myelodysplastic syndrome (MDS). Lenalidomide (LEN) is the first-line therapy for del(5q) MDS, but half of the patients become resistant within 2-3 years, highlighting the need for new treatment options. LEN binds to the substrate adaptor of CRL4CRBN E3 ubiquitin ligase, Cereblon, …
-
Characterizing the mechanism of action of lenalidomide in a mouse model
Lenalidomide is an FDA approved immunomodulatory drug (IMID) that is highly efficacious in myelodysplastic syndrome with del(5q), multiple myeloma, as well as other B cell malignancies.1 Furthermore, lenalidomide promotes a multitude of physiological effects, which include increased IL-2 cytokine …
-
Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation
… therapies in MDS has not been fully discovered. Lenalidomide is a small molecule therapeutic preferentially effective in MDS patients with an interstitial chromosome 5q deletion (del(5q)). Improved erythropoiesis has also been reported to occur in 20-30% of low-risk, non-del(5q) patients. …
-
Regulation of Natural Killer Cells: SHIP-1, 2B4, and Immunomodulation by Lenalidomide
… the effects of an immunomodulating drug, lenalidomide, on the biology and function of healthy NK cells. Lenalidomide is a unique drug that displays immune enhancing functions yet can be cytotoxic to tumor cells. However, lenalidomide treatment can result in immune suppression and severe …
-
Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia
… with no guaranteed cure available. The use of lenalidomide in this cancer has been trialled with little success due to high toxicity. Optimisation of lenalidomide therapy is unlikely to occur without determining the reasons behind this toxicity. This thesis aimed to explore the pharmacokinetics …
-
Interrogation of EpoR Fidelity in Myelodysplastic Syndrome Hematopoiesis and Stabilization by the Immunomodulatory Agent, Lenalidomide
… is the second generation immunomodulatory agent, lenalidomide (LEN). LEN is an analog of the known teratogen, thalidomide, and has broad biological effects including selective cytotoxicity to del(5q) clones, activation of T-cells, and expansion of erythroid precursors. In patients with del(5q) …
-
Selection and characterization of DNA aptamers for therapeutic monitoring of Lenalidomide, 6-Mercaptopurine, Dabrafenib and Venetoclax
… of an aptamermodel to approach monitoring of Lenalidomide (LDM), 6-Mercaptopurine (6-MP), Dabrafenib(DFB) and Venetoclax (VENX) via the Sequential Evolution of Ligands by ExponentialEnrichment (SELEX) process. In this work, DNA aptamers against four commonly used anticancer – Lenalidomide …
-
Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector
… due to their proven high clinical efficacy are lenalidomide plus low-dose dexamethasone (LEN/DEX) and bortezomib monotherapy (BORT). The clinical effectiveness of both regimens for second-line treatment of RRMM was reported in the MM009/010 and the APEX studies, respectively, where each regimen …
-
Correlazioni molecolari fra angiogenesi e neurodegenerazione
… potenziali effetti del farmaco immunomodulante lenalidomide nelle patologie neurodegenerative
-
An unbiased proteomics approach identifies novel cereblon-engaging immunomodulatory imide molecular glues
… assays were profiled in Jurkat T-cells alongside lenalidomide as references. Cells were treated (DMSO vehicle; reference: 10 µM; test compounds: 100 µM; 18 h), proteins were extracted, trypsin-digested and analyzed by nanoLC–MS/MS on a Q-Exactive Plus. Data were processed with FragPipe (1% FDR) …
-
Συστηματική ανασκόπηση: Η Λεναλιδομίδη και ο ρόλος των ανοσοτροποποιητικών φαρμάκων στα Β-Λεμφώματα / Systematic Review: Lenalidomide and the role of immunomodulatory drugs at B-cell Lymphomas
Εισαγωγή: Η λεναλιδομίδη, ένα από του στόματος ανοσοτροποποιητικό φάρμακο, ασκεί άμεση αντικαρκινική και ανοσορρυθμιστική δράση στα λεμφώματα Β-κυττάρων. Παρότι μελέτες φάσης ΙΙ κατέδειξαν τη σκοπιμότητα της χρήσης της, ο ρόλος της σε τυχαιοποιημένες ελεγχόμενες κλινικές μελέτες (RCTs) φάσης ΙΙΙ …
-
AI Assisted Cellular and 3D Spheroid Analyses for Combined Therapies Against Glioblastoma
… using U87 and T98G cell lines, radiation with lenalidomide (RT+Len, immunotherapy) in 3D spheroids, and temozolomide with graphene quantum dots (TMZ+GQD). Microscopy images at 24 and 48 hours were analyzed using k-means and hierarchical clustering with no labels or predetermined features. For …
-
Επιδημιολογική και οικονομική ανάλυση κόστους - συνεπειών της καινοτομίας στην υγεία κατά την περίοδο κρίσης στην Ελλάδα
… of real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Direct …
-
The Role of Cellular and Protein Context in Targeted Protein Degradation
… 1α isoform (CK1α), targeted degradation by lenalidomide led to co-degradation of FAM83F in complex but no other FAM83 protein, suggesting that FAM83F-CK1α complexes can be selectively targeted by lenalidomide. CK1α has several roles in the cell to control processes involved with cell death, …
-
The development and evaluation of small molecule inhibitors of HUWE1 for the treatment of multiple myeloma
… of care therapies: immunomodulatory drug lenalidomide and proteasome inhibitors bortezomib in both WT and mutant HUWE1 cell lines, as well as re-sensitising bortezomib and carfilzomib resistant cells to their respective proteasome inhibitors.<br/><br/><i>Thesis is embargoed until 31 July …
-
Targeted protein degradation in the pathogenesis and therapy of multiple myeloma
… with the development of its more potent analogs, lenalidomide and pomalido-mide, has significantly advanced the therapeutic armamentarium for multiple myeloma. Thalido-mide analogs bind to the protein cereblon (CRBN) and alter the E3 ubiquitin ligase complex's substrate specificity, leading to …
-
Μελέτη της επίδρασης της λεναλιδομίδης και της μπορτεζομίμπης στα ρυθμιστικά Τ-λεμφοκύτταρα σε ασθενείς με πολλαπλούν μυέλωμα
… with Novel Agents (NA) i.e. bortezomib and lenalidomide, are limited. Our aim was to explore possible alterations of Tregs and lymphocyte subpopulations (T4, T8, B, NK, NKL), as well as changes in the levels of cytokines related to Tregs function and MM biology (IL-6, IL-2, IL-17, TGF-β) …
-
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
… were found not to be involved in providing lenalidomide resistance to the cell, whereas knocking CUL4B out was observed to provide negative fitness to the cells in CCA. In the presence of external selection pressure, these clones showed fitness, which was lost in the case of lenalidomide …
-
Ο ρόλος των μονοκλωνικών αντισωμάτων anti-CD38 και anti-SLAMF7 στο πολλαπλό μυέλωμα: από τις προκλινικές μελέτες στις εγκρίσεις κυκλοφορίας
… με τη μελέτη SIRIUS. Ως συνδυαστική θεραπεία με Lenalidomide/dexamethasone με όφελος ORR 31% και μέσο PFS 3.8 μήνες σύμφωνα με τη μελέτη ΜΜΥ3003, σε συνδυασμό με Bortezomib/dexamethasone με όφελος ORR 79.3% σύμφωνα με τη μελέτη CASTOR, σε συνδυασμό με Pomalidomide/dexamethasone με όφελος ORR 60% …
Page 1 of 3